PI3K Pathway Activity and Response to First-Line Chemotherapy in Combination with Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer

被引：0
|
作者：
Vorkas, P. A.
Agelaki, S.
Poumpouridou, N.
Kroupis, C.
Mavroudis, D.
Stathopoulos, E.
Georgoulias, V
Liandou, E. S.
机构：
[1] Univ Athens, Sch Med, GR-11527 Athens, Greece
[2] Univ Gen Hosp Heraklion, Iraklion, Crete, Greece
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：599S / 599S
页数：1
相关论文
共 50 条
  • [1] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [2] Evaluation of first-line trastuzumab in combination with epirubicin/cyclophosphamide for patients with HER2-positive metastatic breast cancer.
    Unich, M.
    Tjulandin, S.
    Jonat, W.
    Meerpohl, H.
    Lichinitser, M.
    Manikhas, G. M.
    Janicke, F.
    Muscholl, M.
    Pausehinger, M.
    Thomssen, C.
    Leide, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S185 - S186
  • [3] Characterization of response to first-line chemotherapy, trastuzumab, and pertuzumab among patients with de novo metastatic HER2-positive breast cancer
    Ferraro, Emanuela
    Khan, Atif
    Plitas, George
    Chen, Yuan
    Ahmed, Mehnaj
    An, Julia
    Dang, Chau
    Robson, Mark
    Chandarlapaty, Sarat
    Modi, Shanu
    Razavi, Pedram
    Shen, Sherry
    CANCER RESEARCH, 2024, 84 (09)
  • [4] Capacitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC)
    Chan, A.
    Yamamoto, D.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Components of the PI3K/Akt pathway as prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab
    Veenstra, C.
    Ellegard, S.
    Perez-Tenorio, G.
    Fagerstrom, V.
    Garsjo, J.
    Briedis, K.
    Sundqvist, M.
    Malmstrom, A.
    Wingren, S.
    Stal, O.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Pier Paolo M. Berton Giachetti
    Giuseppe Curigliano
    Nature Reviews Clinical Oncology, 2024, 21 : 171 - 172
  • [7] Cardiac safety of trastuzumab in combination with epirubicin/cyclophosphamide as first-line therapy in patients with HER2-positive metastatic breast cancer
    Untch, M.
    Tjulandin, S.
    Jonat, W.
    Meerpohl, H.
    Lichinitser, M.
    Manikhas, G. M.
    Jaenicke, F.
    Muscholl, M.
    Pauschinger, M.
    Lehle, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 216 - 216
  • [8] Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Giachetti, Pier Paolo M. Berton
    Curigliano, Giuseppe
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 171 - 172
  • [9] PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations
    Chung, Wei-Pang
    Huang, Wei-Lun
    Lee, Chun-Hui
    Hsu, Hui-Ping
    Huang, Wan-Ling
    Liu, You-Yu
    Su, Wu-Chou
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (07): : 3067 - +
  • [10] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Farhat, Fadi
    Kattan, Joseph G.
    Ghosn, Marwan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1069 - 1077
12345